Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AML classification in the year 2023: How to avoid a Babylonian confusion of languages
Sandra Huber, Constance Baer, Stephan Hütter, et al.
Leukemia (2023) Vol. 37, Iss. 7, pp. 1413-1420
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

A new genomic framework to categorize pediatric acute myeloid leukemia
Masayuki Umeda, Jing Ma, Tamara Westover, et al.
Nature Genetics (2024) Vol. 56, Iss. 2, pp. 281-293
Open Access | Times Cited: 34
Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Menglin Li, Yimeng Li, Qingyuan Qu, et al.
Cancer Letters (2025), pp. 217460-217460
Closed Access | Times Cited: 2
Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML
Diana Macečková, Lenka Vaňková, Monika Holubová, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 6
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group
Carlos Jiménez‐Vicente, Paola Charry, Sandra Castaño‐Díez, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 1, pp. 256-267
Closed Access | Times Cited: 5
A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria
Qianghua Zhou, Davidson Zhao, Mojgan Zarif, et al.
Blood Advances (2024) Vol. 8, Iss. 7, pp. 1760-1771
Open Access | Times Cited: 5
Application of RNA-Based Next-Generation Sequencing Fusion Assay for Hematological Malignancies
Fei Fei, Milhan Telatar, Vanina Tomasian, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 435-435
Open Access
Novel classification system and high-risk categories of pediatric acute myeloid leukemia
Masayuki Umeda, Yen‐Chun Liu, Seth E. Karol, et al.
Haematologica (2025)
Open Access
Myeloid neoplasms with MYC-positive double minutes: towards recognition as a distinct entity
Isolde Summerer, Wencke Walter, Manja Meggendorfer, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia With Myelodysplasia‐Related Genetic Features: Relevance of the Genetic Underlying Category. A Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT
Jordi Esteve, Arnon Nagler, Myriam Labopin, et al.
American Journal of Hematology (2025)
Closed Access
Allogeneic stem cell transplantation for MDS—clinical issues, choosing preparative regimens and outcome
Lara Bischof, Lara Bischof, Uwe Platzbecker, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-14
Open Access
An Overview on Lipid Droplets Accumulation as Novel Target for Acute Myeloid Leukemia Therapy
Clelia Nisticò, Emanuela Chiarella
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3186-3186
Open Access | Times Cited: 9
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes
Johann-Christoph Jann, Christopher A. Hergott, Marisa Winkler, et al.
Leukemia (2024) Vol. 38, Iss. 9, pp. 1992-2002
Open Access | Times Cited: 3
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC
Wenbin Xiao, Valentina Nardi, Eytan M. Stein, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 3
The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression
Diego Cuevas, Roberto Amigo, Adolfo Agurto, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1915-1915
Open Access | Times Cited: 2
Flow cytometry in acute myeloid leukemia and detection of minimal residual disease
Qihui Cai, Haiqiang Lan, Yi Deng, et al.
Clinica Chimica Acta (2024) Vol. 564, pp. 119945-119945
Open Access | Times Cited: 2
Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations
Tian‐Hua Wei, Zixuan Wang, Meng‐Yi Lu, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 2
Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
Sandra Huber, Constance Baer, Stephan Hütter, et al.
Leukemia (2023) Vol. 37, Iss. 10, pp. 2138-2141
Open Access | Times Cited: 6
Improving long-term outcomes with intensive induction chemotherapy for patients with AML
Christoph Röllig
Hematology (2023) Vol. 2023, Iss. 1, pp. 175-185
Closed Access | Times Cited: 5
Reporting bone marrow biopsies for myelodysplastic neoplasms and acute myeloid leukaemia incorporating WHO 5th edition and ICC 2022 classification systems: ALLG/RCPA joint committee consensus recommendations
Ashley P. Ng, Rebecca Adams, Ing Soo Tiong, et al.
Pathology (2024) Vol. 56, Iss. 4, pp. 459-467
Closed Access | Times Cited: 1
The CDK4/6 inhibitor Palbociclib synergizes with ATRA to induce differentiation in AML
Linhui Hu, Qian Li, Jiyu Wang, et al.
Molecular Cancer Therapeutics (2024) Vol. 23, Iss. 7, pp. 961-972
Closed Access | Times Cited: 1
Diagnosis and Reclassification of Myelodysplastic Syndromes and Acute Myeloid Leukemia: Comparison Between the 2016 WHO 4th and 2022 WHO 5th/ICC Classifications
Su Min Han, Sang Hyuk Park, Hyun‐Ki Kim, et al.
Laboratory Medicine Online (2024) Vol. 14, Iss. 3, pp. 208-217
Closed Access | Times Cited: 1
CREST‐UK: Real‐world effectiveness, safety and outpatient delivery of CPX‐351 for first‐line treatment of newly diagnosed therapy‐related AML and AML with myelodysplasia‐related changes in the UK
Priyanka Mehta, Victoria Campbell, Jamie Maddox, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 1
Deciphering the Complexities of Acute Myeloid Leukemia: Emerging Roles of Epithelial to Mesenchymal Transition Transcription Factors (EMT-TFs) in Disease Progression
Diego Cuevas, Roberto Amigo, Adolfo Agurto, et al.
(2024)
Open Access | Times Cited: 1
Novel insights and therapeutic approaches in secondary AML
Giovanni Marconi, Michela Rondoni, Beatrice Anna Zannetti, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Whole Exome Sequencing of Intermediate-Risk Acute Myeloid Leukemia without Recurrent Genetic Abnormalities Offers Deeper Insights into New Diagnostic Classifications
Francesca Guijarro, Sandra Castaño‐Díez, Carlos Jiménez‐Vicente, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8669-8669
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top